Liliana Garcia-Martinez

Liliana Garcia-Martinez

Auto-generated profile, based on publicly available information

Liliana Garcia-Martinez

Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
LGLiliana Garcia-Martinez
Liliana Garcia-Martinez
YZYusheng Zhang
Yusheng Zhang
YNYuichiro Nakata
Yuichiro Nakata
HCHo Lam Chan
Ho Lam Chan
Lluis MoreyLluis Morey
Lluis Morey
The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this pathway represent the main treatment modality. Endocrine therapy has proven successful in the treatment of hormone-responsive breast cancer since its early adoption in the 1940s as an ablative therapy. Unfortunately, therapeutic resistance arises, leading to disease recurrence and relapse. Recent studies increased our understanding in how changes to the chromatin landscape and deregulation of epigenetic factors orchestrate the resistant phenotype. Here, we will discuss how the epigenome is an integral determinant in hormone therapy response and why epigenetic factors are promising targets for overcoming clinical resistance.

5 June 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
YZYusheng Zhang
Yusheng Zhang
HCHo Lam Chan
Ho Lam Chan
LGLiliana Garcia-Martinez
Liliana Garcia-Martinez
DKDaniel L. Karl
Daniel L. Karl
NWNatalia Weich
Natalia Weich
Lluis MoreyLluis Morey
Lluis Morey
RING1B co-operates with ERα to regulate estrogen-mediated gene and enhancer activities and chromatin reorganization.

7 November 2022 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
LGLiliana Garcia-Martinez
Liliana Garcia-Martinez
AAAndrew M. Adams
Andrew M. Adams
HCHo Lam Chan
Ho Lam Chan
YNYuichiro Nakata
Yuichiro Nakata
NWNatalia Weich
Natalia Weich
Lluis MoreyLluis Morey
Lluis Morey

11 April 2025 in Science Advances
Verified
Journal Article
Open access
FYFengyao Yan
Fengyao Yan
ATAristeidis G Telonis
Aristeidis G Telonis
QYQin Yang
Qin Yang
LJLimin Jiang
Limin Jiang
FGFrancine E. Garrett-Bakelman
Francine E. Garrett-Bakelman
Yan GuoYan Guo
Yan Guo
Using millions of methylation segments, we developed DiffuCpG, a generative artificial intelligence (AI) diffusion model designed to solve the critical challenge of missing data in high-throughput methylation technologies. DiffuCpG goes beyond conventional methods by leveraging both short-range interactions including nearby CpGs from both latitude and longitude of the dataset, local DNA sequences, and long-range interactions, including three-dimensional genome architecture and long-distance correlations, to comprehensively model the methylome. Compared to previous methods, through extensive independent validations across different tissue types, cancers, and technologies (whole-genome bisulfite sequencing, enhanced reduced representation bisulfite sequencing, single-cell bisulfite sequencing, and methylation arrays), DiffuCpG has demonstrated superior performance in accuracy, scalability, and versatility. On average, bisulfite sequencing dataset, DiffuCpG can extend the original dataset by millions of additional CpGs. As an alternative application of generative AI, DiffuCpG addresses a key bottleneck in epigenetic research and will substantially benefit studies relying on high-throughput methylation data.

11 December 2025 in Cancer Research
Verified
Journal Article
Closed access
SKSrushti Kittane
Srushti Kittane
ELErik Ladewig
Erik Ladewig
TLTaibo Li
Taibo Li
JLJillian R. Love
Jillian R. Love
RBRyan Blawski
Ryan Blawski
ETEneda Toska
Eneda Toska
Castration-resistant prostate cancer (CRPC) is largely dependent on the androgen receptor (AR) for growth and often exhibits hyperactive PI3K signaling, most frequently because of PTEN loss. Therapeutic pressure from anti-AR therapies can induce transdifferentiation toward an AR-independent phenotype. Recently, different subtypes of AR-independent CRPC have been redefined, with the stem cell–like (SCL) subtype emerging as one of the most prevalent. Elucidation of the epigenetic mechanisms controlling the maintenance of these distinct CRPC cell states could pave the way for effective combinatorial therapies for CRPC. In this study, we identified a key role for the histone methyltransferase KMT2D in establishing the chromatin competence necessary for the recruitment of AR and FOXA1 transcription factors (TF) that are essential for the AR transcriptional output in AR-dependent CRPC cell lines, patient-derived organoids, and patient samples. Unexpectedly, KMT2D maintained the identity of the AR-low CRPC-SCL subtype and controlled activity of AP-1 TFs such as FOSL1, which acts as a master regulator of this subtype. Single-cell transcriptomics and chromatin assays underscored the role of KMT2D in sustaining a mixed lineage cell state via AP-1 and FOXA1. The combined suppression of PI3K/AKT and KMT2D reduced cell proliferation in prostate cancer cells and patient-derived organoids in both CRPC-AR and CRPC-SCL subtypes. Altogether, these results unveil KMT2D as a major mediator of the epigenetic landscape in subtype-specific CRPC, contributing to tumor growth and therapeutic response. Significance: KMT2D is a critical regulator of chromatin accessibility and transcriptional landscapes in castration-resistant prostate cancer that drives both AR-dependent and AR-independent subtypes, highlighting KMT2D as a potential therapeutic target.

14 August 2025 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
ATAristeidis G Telonis
Aristeidis G Telonis
AHAlexandra E Hernandez
Alexandra E Hernandez
PBPeter A. Borowsky
Peter A. Borowsky
EHElizabeth D. Reguero Hernandez
Elizabeth D. Reguero Hernandez
PLPeter Lyon
Peter Lyon
NGNeha Goel
Neha Goel
Background: Social adversity from neighborhood disadvantage (ND) is associated with shorter breast cancer survival. Although studies have identified associations between ND and DNA methylation (DNAme) or gene expression (mRNA), a study integrating DNAme and mRNA to understand how the epigenome regulates key biological pathways in ND merits further inquiry. Methods: DNAme-, mRNA-, miRNA-, and tRNA-derived fragment data were analyzed from 80 estrogen receptor+/HER2− breast cancer samples. We analyzed the association among ND, DNAme, coding, and noncoding data to understand how the epigenome regulates biological pathways. Results: Twenty-five patients lived in ND and 55 in neighborhood advantage. In patients from ND, calcium signaling and cell adhesion pathways were hypermethylated, immune-related pathways hypomethylated, immune response genes upregulated, and estrogen response genes downregulated. Small RNA analysis showed differential expression of miRNA isoforms and tRNA-derived fragments related to ND. Subjective ND further correlated with epigenetic changes in calcium signaling, cell adhesion, and metabolic pathways, along with upregulation of proliferative and stemness pathways. Conclusions: We discovered novel associations between ND and epigenomic regulation of clinically relevant oncogenesis pathways associated with aggressive biology, such as estrogen response pathways. These findings lay the foundation for multi-institutional studies to validate our findings. Impact: This study demonstrates that ND, which is associated with shorter breast cancer survival, is also associated with epigenetic reprogramming of key oncogenesis pathways. These findings highlight pathways through which ND may affect tumor biology and lay the foundation for cancer control policy and behavioral interventions that may reverse the negative effects of ND on cancer biology.